Hormone pills before prostate cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests two oral hormone drugs (darolutamide and relugolix) given before prostate removal surgery for men with high-risk prostate cancer. The goal is to see if this combination shrinks the tumor and improves treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk prostate cancer (Gleason score 4+3 or higher, with multiple positive biopsies or a PSA over 20).
- You are scheduled to have your prostate removed (radical prostatectomy).
- You are able to swallow pills and are generally healthy enough for daily activities (ECOG 0–1).
- You have not taken any similar hormone treatments (like Lupron or Xtandi) in the past year.
- You have not had a heart attack, stroke, or severe heart failure in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a hormone-blocking drug called darolutamide can shrink aggressive prostate cancer before surgery. Researchers will also use a special blood test to predict who benefits most from the treatment.
This trial tests a combination of darolutamide (a hormone-blocking pill) and standard hormone therapy (ADT) given before prostate surgery. It is for men with high-risk prostate cancer that has not spread to distant parts of the body, to see if the treatment can improve outcomes.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
This trial tests darolutamide (a hormone blocker pill) with or without standard hormone therapy given before surgery for high-risk prostate cancer. The goal is to see if this combination can shrink the cancer and improve outcomes before the prostate is removed.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
Hear when a new Prostate CA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.